Treatment & Management

Bisphosphonate linked to atrial fibrillation

04/03/2010 | An Australian specialist is warning practitioners to be cautious when using the bisphosphonate alendronate in patients with a history of cardiac arrhythmia after finding the drug was associated with a higher incidence of atrial fibrillation.


Avandia safety debate continues

04/03/2010 | A document released by the Committee on Finance of the US Senate once again highlights the health risks associated with rosiglitazone (Avandia) but an advisory published by the American Heart Association says the evidence is still limited and inconclusive.


Kidney disease requires local action

04/03/2010 | Countries must urgently take local action to increase awareness of diabetic kidney disease and address its ramifications for global health, an Australian specialist says.


Role for raloxifene in postmenopausal women with schizophrenia

24/02/2010 | The selective oestrogen receptor modulator raloxifene may have a role in treating postmenopausal women with schizophrenia, a small pooled analysis finds.


Placebos provide benefit

24/02/2010 | The placebo effect is far more than an inert treatment and instead represents a "genuine psychobiological event", according to a review in The Lancet co-authored by Sydney pain specialist Dr Damien Finniss.


Advisory warns of CV risk with androgen therapy

09/02/2010 | The use of androgen deprivation therapy for prostate cancer may increase cardiovascular risk factors and the risk for myocardial infarction and cardiac death, a scientific advisory has warned.


More support for aspirin in diabetes

04/02/2010 | Australian research has strengthened the case for giving daily low-dose aspirin to patients with diabetes but no history of CVD.


Device slows eating

04/02/2010 | A computerised device that re-trains eating behaviours can significantly reduce BMI, an obesity clinic has found.


Androgen replacement supported for postmenopausal low libido

28/01/2010 | Evidence supports the efficacy of testosterone therapy for postmenopausal women with hypoactive sexual desire disorder but clinicians still have questions about whether the disorder warrants treatment and how therapy should be delivered, according to Melbourne endocrinologist Susan Davis.


Androgen replacement supported for postmenopausal low libido

25/01/2010 | Evidence supports the efficacy of testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD) but clinicians still have questions about whether the disorder warrants treatment and how therapy should be delivered, according to Melbourne endocrinologist Susan Davis.


More Treatment & Management news

Journals

Members of Endocrinology Update can access the following journals for free:

Recent comments

Most viewed articles this week

Related sites